Inflammatory endotypes and biomarker-guided patient stratification for anti-inflammatory therapies

alzheimers proposed composite 67%
Open a bounty challenge Fund this gap and accept submissions. SPEC-033.
Composite
67%
Novelty
—
Mechanistic
—
Druggability
—
Priority
67%
Importance
67%
Tractability
—
Market price
50%

Description

While inflammation is recognized as central to AD pathogenesis, no validated inflammatory endotypes exist to guide personalized anti-inflammatory treatment selection. Blood or CSF biomarkers enabling stratification are absent.